Imipramine in the treatment of agoraphobia: dose-response relationships

Publisher Website
Google Scholar
Abstract
Dose-response relationships were examined in 62 agoraphobic patients receiving either imipramine or placebo under double-blind conditions in conjuction with behavioral interventions. At the end of 12 wk, patients treated with imipramine had improved significantly more than placebo patients. The beneficial therapeutic effect of imipramine was dose dependent. Optimal response in agoraphobia may require doses of 150 mg/day or more. Side effects apparently can significantly interfere with the buildup of optimal dose in agoraphobic patients treated with imipramine.

This publication has 17 references indexed in Scilit: